Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Current Leases: 2019-2024

Historic Current Leases for Ocular Therapeutix (OCUL) over the last 6 years, with Dec 2024 value amounting to $1.9 million.

  • Ocular Therapeutix's Current Leases rose 60.86% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 60.86%. This contributed to the annual value of $1.9 million for FY2024, which is 21.88% up from last year.
  • Per Ocular Therapeutix's latest filing, its Current Leases stood at $1.9 million for FY2024, which was up 21.88% from $1.6 million recorded in FY2023.
  • Ocular Therapeutix's Current Leases' 5-year high stood at $1.9 million during FY2024, with a 5-year trough of $1.4 million in FY2020.
  • For the 3-year period, Ocular Therapeutix's Current Leases averaged around $1.7 million, with its median value being $1.6 million (2022).
  • As far as peak fluctuations go, Ocular Therapeutix's Current Leases dropped by 1.54% in 2022, and later climbed by 21.88% in 2024.
  • Ocular Therapeutix's Current Leases (Yearly) stood at $1.4 million in 2020, then increased by 19.59% to $1.6 million in 2021, then dropped by 1.54% to $1.6 million in 2022, then fell by 0.81% to $1.6 million in 2023, then grew by 21.88% to $1.9 million in 2024.